Genmab Reports 28.2-Month Median Overall Survival in Phase 2 Combination Study
Genmab reported median overall survival of 28.2 months for petosemtamab plus pembrolizumab in first-line PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. The Phase 2 update included an ORR of 63% (CR 19%) and median PFS of 9.0 months among 43 patients, with no treatment-related deaths reported.